Navigation Links
NUCRYST announces 2009 first quarter financial results
Date:5/6/2009

PRINCETON, NJ, May 6 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp., a developer and manufacturer of medical products that fight infection and inflammation, today announced its financial results for the first quarter of 2009.

For the quarter ended March 31, 2009, NUCRYST reported a net loss of $1.1 million, or $0.06 cents per share, on revenues of $4.1 million. This compares to a net loss of $2.2 million, or $0.12 cents per share, on revenues of $5.2 million in the first quarter of 2008.

At March 31, 2009, NUCRYST had $8.4 million in cash and cash equivalents, compared to $23.4 million at December 31, 2008. In the first quarter of 2009, NUCRYST completed a $14.7 million, or $0.80 per share, cash distribution to NUCRYST shareholders.

"With the return of capital to our shareholders in the first quarter of 2009, we are taking the necessary steps to reduce our cost structure to an appropriate level," said David B. Holtz, Interim President and Chief Executive Officer, and Chief Financial Officer of NUCRYST. "We remain focused on driving the Company towards a sustainable level of profitability while continuing to explore strategic alternatives for the business."

First quarter financial analysis

NUCRYST's total revenue which consists of wound care product revenues less the manufacturing cost rebate for the first quarter of 2009 decreased to $4.1 million compared to $5.2 million in the first quarter of 2008. The decline was due to lower product shipments in the first quarter of 2009 and lower royalty revenues as a result of lower US dollar sales of Acticoat(TM) reported by Smith & Nephew plc. Smith & Nephew's reported Acticoat(TM) sales were negatively impacted by the strengthening U.S. dollar.

Gross margin on product revenues was 46% in the first quarter of 2009, compared to 21% in the first quarter of 2008. The improvement is primarily the result of cost reductions achieved through ma
'/>"/>

SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
2. NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results
3. NUCRYST Approves $0.80 Per Share Cash Distribution to Shareholders
4. NUCRYST appoints interim CEO
5. NUCRYST Pharmaceuticals appoints a new director
6. NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder
7. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
8. NUCRYST Receives Deficiency Notice from NASDAQ
9. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
10. NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer
11. NUCRYST Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... 20, 2014 Ticket Down is ... . This popular ticket exchange is offering their customer ... The 2015 schedule of tours is beginning to fill up. ... their plans to hit the road, including 21-year-old pop superstar, ... the “Honeymoon Tour,” which will take her to 25 cities ...
(Date:9/20/2014)... 20, 2014 On Monday, September 22, ... pediatric cancer research grant from Hyundai Hope on Wheels ... Children’s Hospital located on 11234 Anderson St., in Loma ... Kimberley Payne, Associate Professor at Loma Linda University and ... leukemia in children. , Loma Linda University ...
(Date:9/20/2014)... 20, 2014 The print component ... edition of the Calgary Herald, with a circulation ... of 270,000. The digital component is distributed nationally ... a network of top news sites and partner ... campaign, visit http://www.worklifebalanceinfo.ca . , The publication ...
(Date:9/20/2014)... -- The avian flu that killed 160 harbor seals ... respiratory drops and therefore poses a potential threat to ... human illnesses have been linked to the harbor seal ... discovered natural mutations to the avian H3N8 seal virus ... in droplets. Current seasonal flu vaccines wouldn,t help ...
(Date:9/20/2014)... season is coming soon. The high-end fashion designer BellasDress is ... . A lot of sophisticated women like its new items. ... for its high quality clothes. Now, each of its elegant ... 71 percent off. , The company’s cocktail dress assortment ... many fashionable colors. Mary, the company’s sales manager, believes that ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:Avian Flu In Harbor Seals Could Infect People 2Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2
... Commitment to Active Listening , ROCHESTER, ... Tomaino specializes in cutting-edge shoulder procedures including everything ... a reversed shoulder replacement that relieves pain, restores ... is also adept at the practice of active ...
... another reason for people to watch their blood pressure, ... that increased blood pressure in older adults is directly ... already high blood pressure. This means that stressful situations ... think clearly. , Dr. Jason Allaire, an assistant professor ...
... LONDON, Dec. 15 The immunoassay diagnostics market is ... It is being challenged by a number of factors ... the heightened popularity of molecular tests in areas like ... propelling companies to develop novel assays and differentiate themselves ...
... Dec. 15 Roche announced today that its,innovative ... allowing,it to be sold for clinical use in ... Test, v2.0 utilizes a unique design to,simultaneously amplify ... genome.,This approach provides reliable test results even when ...
... possible new therapeutic target for pancreatic cancer, the most ... the proteins whose DNA recipe comes from gene, "Seven-In-Absentia," ... Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in ... fruit fly, Drosophila melanogaster, at the Mayo Clinic College ...
... featured in an upcoming episode. , ... Deerfield Beach, FL (PRWEB) December ... announce that Gradient Medical, LLC will be featured in an upcoming episode ... Today., , ,Pain is a national public healthcare crisis. It is estimated ...
Cached Medicine News:Health News:Rochester Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care 2Health News:Rochester Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care 3Health News:Rochester Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care 4Health News:Development of Novel Assays Vital for the European Immunoassay Diagnostics Market 2Health News:Development of Novel Assays Vital for the European Immunoassay Diagnostics Market 3Health News:New Roche Dual Target HIV-1 Test Approved for Use in European Union 2Health News:New Roche Dual Target HIV-1 Test Approved for Use in European Union 3Health News:Blocking molecular pathway with whimsical name possible therapeutic target for pancreatic cancer 2Health News:"The Economic Report" Show to Feature Gradient Medical, LLC 2
(Date:9/19/2014)... DIEGO , Sept. 19, 2014  Lpath, ... leader in bioactive lipid-targeted therapeutics, announced today that ... 3,605,042 registered shares of common stock and 3,605,042 ... combined purchase price for one registered share of ... one unregistered share of common stock will be ...
(Date:9/19/2014)... and ORLANDO, Fla. , Sept. 19, ... therapy continues to grow, with the publication of two ... in Otolaryngology – Head and Neck Surgery ... worsening of both objective and subjective measures of sleep ... Inspire therapy for the reduction in obstructive sleep apnea ...
(Date:9/19/2014)... 2014  Over 200 runners participated in the fifth ... Radiation Oncology Institute (ROI), hosted by Radiation Business Solutions. This ... in San Francisco.  "Donations are still ... Radiation Business Solutions, "but at this point, through ... for the ROI this year. This surpasses last year,s ...
Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... Rochester Medical Corporation (Nasdaq: ROCM ) today announced that it is ... healthcare alliance. , , , ... with more than 800 suppliers and Rochester Medical is one of 38 ... outstanding management of Premier agreements and drive toward the mutual goal of ...
... June 22 Hospira, Inc. (NYSE: HSP ... it has received U.S. Food and Drug Administration (FDA) approval ... g vials.  The medication, a carbapenem that belongs to the ... Merrem® I.V. Sales of the name-brand product in ...
Cached Medicine Technology:Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance 2Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance 3Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.) 2Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.) 3
Thru cut kerrison style punch 30 deg, 2.75 X 1.4 mm cut, 110 working length....
6 mm, 45 degree upwards, detachable....
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
Sabre 180 is a powerful niche generator....
Medicine Products: